Recursion Pharmaceuticals Income Statement (2020-2025) | RXRX

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.06M0.19M1.02M2.69M2.56M2.55M2.53M2.53M5.33M7.67M13.16M13.68M12.13M11.02M10.53M10.89M13.79M14.42M26.08M4.55M14.74M19.22M5.17M
Cost of Revenue 7.80M14.23M15.41M10.84M12.45M9.38M10.88M9.88M11.17M9.20M12.08M12.79M21.83M20.16M14.69M
Gross Profit -2.47M-6.55M-2.25M2.84M-0.31M1.64M-0.34M1.01M2.63M5.22M14.00M-8.25M-7.08M-0.94M-9.51M
Operating items
Research & Development 12.84M13.24M16.54M20.70M24.11M29.62M33.25M48.29M32.44M38.44M40.84M43.98M46.68M55.06M70.01M69.48M67.56M73.93M74.60M98.33M129.63M128.64M121.06M
Selling, General & Administrative 5.56M5.16M6.96M7.57M8.94M13.85M15.69M19.20M21.07M21.20M19.49M19.84M22.87M28.29M29.20M30.46M31.41M31.83M37.76M77.19M54.65M46.65M41.63M
Other Operating Expenses 7.80M14.23M15.41M10.84M12.45M9.38M10.88M9.88M11.17M9.20M12.08M12.79M21.83M20.16M14.69M
Operating Expenses 18.40M18.40M23.50M28.27M33.05M43.48M48.94M67.49M61.31M73.86M75.73M74.66M82.00M92.73M110.08M109.82M110.13M114.96M124.44M188.31M206.11M195.45M177.38M
Operating Income -18.34M-18.22M-22.47M-25.58M-30.48M-40.93M-46.40M-64.96M-55.98M-66.19M-62.57M-60.98M-69.86M-81.72M-99.55M-98.93M-96.34M-100.54M-98.35M-183.77M-191.37M-176.23M-172.20M
EBIT -18.34M-18.22M-22.47M-25.58M-30.48M-40.93M-46.40M-64.96M-55.98M-66.19M-62.57M-60.98M-69.86M-81.72M-99.55M-98.93M-96.34M-100.54M-98.35M-183.77M-191.37M-176.23M-172.20M
Non-operating items
Non Operating Income -0.08M-0.73M-1.40M-0.18M-0.23M-2.47M-1.03M0.03M0.00M0.63M2.13M3.49M4.54M4.99M6.53M1.87M4.19M2.48M2.68M4.87M-11.28M4.33M9.95M
Net income details
EBT -18.34M-18.22M-22.47M-25.58M-30.48M-40.93M-46.40M-64.96M-55.98M-66.19M-62.57M-60.98M-65.33M-76.73M-93.02M-97.06M-92.15M-98.06M-95.67M-178.90M-202.65M-171.90M-162.25M
Tax Provisions -4.06M-0.78M-0.52M0.17M0.01M-0.16M0.00M
Profit After Tax -18.42M-18.94M-23.87M-25.77M-30.72M-43.40M-47.43M-64.93M-55.98M-65.56M-60.45M-57.49M-65.33M-76.73M-93.02M-93.00M-91.37M-97.54M-95.84M-178.91M-202.49M-171.90M-162.25M
Income from Non-Controlling Interests -18.42M18.94M-30.72M43.40M
Income from Continuing Operations -18.34M-18.22M-22.47M-25.58M-30.48M-40.93M-46.40M-64.96M-55.98M-66.19M-62.57M-60.98M-65.33M-76.73M-93.02M-93.00M-91.37M-97.54M-95.84M-178.91M-202.49M-171.90M-162.25M
Consolidated Net Income -18.34M-18.22M-22.47M-25.58M-30.48M-40.93M-46.40M-64.96M-55.98M-66.19M-62.57M-60.98M-65.33M-76.73M-93.02M-93.00M-91.37M-97.54M-95.84M-178.91M-202.49M-171.90M-162.25M
Income towards Parent Company -18.34M-18.22M-22.47M-25.58M-30.48M-40.93M-46.40M-64.96M-55.98M-66.19M-62.57M-60.98M-65.33M-76.73M-93.02M-93.00M-91.37M-97.54M-95.84M-178.91M-202.49M-171.90M-162.25M
Net Income towards Common Stockholders -18.34M-18.22M-22.47M-25.58M-30.48M-40.93M-46.40M-64.96M-55.98M-66.19M-62.57M-60.98M-65.33M-76.73M-93.02M-93.00M-91.37M-97.54M-95.84M-178.91M-202.49M-171.90M-162.25M
Additional items
EPS (Basic) -0.85-0.88-1.09-1.17-1.33-0.31-0.28-0.39-0.33-0.38-0.35-0.30-0.34-0.38-0.43-0.42-0.39-0.40-0.34-0.57-0.50-0.41-0.36
EPS (Weighted Average and Diluted) -0.85-0.88-1.09-1.17-1.33-0.31-0.28-0.39-0.33-0.38-0.35-0.30-0.34-0.38-0.43-0.42-0.39-0.40-0.34-0.57-0.50-0.41-0.36
Shares Outstanding (Weighted Average) 159.91M159.91M168.32M168.48M168.99M170.77M172.01M173.08M189.56M191.23M192.36M215.59M216.62M234.65M237.66M281.11M286.64M401.99M406.50M434.15M
Shares Outstanding (Diluted Average) 21.64M21.65M21.82M21.78M23.04M138.36M168.53M125.35M170.69M172.21M173.44M175.54M191.62M201.42M214.33M207.85M236.02M242.20M282.58M274.21M402.77M417.36M446.99M
EBITDA -18.34M-18.22M-22.47M-25.58M-30.48M-40.93M-46.40M-64.96M-55.98M-66.19M-62.57M-60.98M-65.33M-76.73M-93.02M-98.93M-91.37M-97.54M-95.84M-183.77M-191.37M-176.23M-172.20M
Tax Rate 4.19%0.85%0.53%0.08%